Fulvestrant Versus Capecitabine as Maintenance Therapy After First-line Chemotherapy in Patients With HR+/HER2- Metastatic Breast Cancer

Trial Details

NCT ID

NCT04263298

Phase

PHASE3

Sponsor

Herui Yao

Status

RECRUITING

Cancer Type

ER/PR Positive (Hormone Receptor Positive) Breast Cancer

Interventions

• Fulvestrant
• Capecitabine Oral Product

Locations (sample)

• Guangzhou, Guangdong, China|23.11667,113.25
• Guangzhou, Guangdong, China|23.11667,113.25
• Guangzhou, Guangdong, China|23.11667,113.25
• Guangzhou, Guangdong, China|23.11667,113.25
• Guangzhou, Guangdong, China|23.11667,113.25

Key Eligibility Criteria

• Adult female patients with advanced breast cancer diagnosed by pathology (aged 18-75, including 18 and 75 years old), not suitable for surgical res…
• Pathological examination confirmed ER and / or PR positive, HER-2 negative (Positive ER expression: immunohistochemistry \>1% tumor cell staining; …
• Patients with advanced breast cancer who have no disease progression after a 4-8-course first-line chemotherapy regimen (the effect is evaluated as…
• WHO physical status 0-1 points, estimated lifetime at least 3 months;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.